spacer
The Healthcare Sales & Marketing Network celebrates 24 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  rimegepant 

 HSMN NewsFeed - 25 Feb 2022
Biohaven and Pfizer Receive Positive CHMP Opinion for Migraine Treatment
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 25 Feb 2022
Biohaven Licenses Taldefgrobep Alfa, a Phase 3-Ready Anti-Myostatin Adnectin for Spinal Muscular Atrophy (SMA), from Bristol Myers Squibb
Biopharmaceuticals Licensing
 HSMN NewsFeed - 14 Feb 2022
Biohaven and Pfizer Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea
Biopharmaceuticals Neurology
 HSMN NewsFeed - 6 Dec 2021
Biohaven Names CEO Vlad Coric, MD, Chairman Of The Board Of Directors And Matthew Buten, Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Nov 2021
NURTEC(R) ODT Approved In Kuwait For Acute Treatment Of Migraine
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 Sep 2020
BioShin, Biohaven's Asia-Pacific Subsidiary, Raises $60M in Series A Funding to Advance Neuroscience Pipeline in Asia-Pacific Region
Biopharmaceuticals Personnel Venture Capital
 HSMN NewsFeed - 10 Jun 2020
Biohaven Appoints Bob Hugin to its Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 23 Mar 2020
Biohaven to Advance Vazegepant into Phase 3 for the Acute Treatment of Migraine Following Successful End of Phase 2 Meeting with FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Mar 2020
Biohaven's Verdiperstat Receives Fast Track Designation For The Treatment Of Multiple System Atrophy
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Feb 2020
Biohaven's Troriluzole Study For Generalized Anxiety Disorder (GAD) Misses Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 10 Dec 2018
Biohaven Announces Positive Results from Ongoing Rimegepant Long-Term Safety Study
Biopharmaceuticals Neurology
 HSMN NewsFeed - 12 Sep 2018
Biohaven Announces Submission of IND for BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist for the Treatment of Migraine
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 28 Jun 2018
Biohaven Expands Rimegepant Development Program to Include New Prevention of Migraine Phase 3 Trial and Highlights Key Late-Breaking Presentations at American Headache Society (AHS) Annual Scientific Meeting
Biopharmaceuticals
 HSMN NewsFeed - 16 Nov 2017
Biohaven Completes Enrollment In The First Of Two Pivotal Phase 3 Clinical Trials Of Rimegepant, A Second Generation Oral CGRP-Receptor Antagonist, For The Acute Treatment Of Migraine
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 Oct 2017
Biohaven Reports Negative Topline Data from Spinocerebellar Ataxia (SCA) Phase 2/3 Trial
Biopharmaceuticals Neurology
 HSMN NewsFeed - 4 Aug 2017
Biohaven Appoints Julia P. Gregory to Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 31 Jul 2017
Biohaven Initiates Second Pivotal Phase 3 Clinical Trial of Oral CGRP Antagonist for the Acute Treatment of Migraine
Biopharmaceuticals Neurology
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.